vs
Side-by-side financial comparison of American Assets Trust, Inc. (AAT) and ADMA BIOLOGICS, INC. (ADMA). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $110.6M, roughly 1.3× American Assets Trust, Inc.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 6.1%, a 29.4% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 1.8%). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -0.1%).
Personal Assets Trust is a large British investment trust. The company is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index. The chairman is Iain Ferguson CBE.
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
AAT vs ADMA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $110.6M | $139.2M |
| Net Profit | $6.7M | $49.4M |
| Gross Margin | — | 63.8% |
| Operating Margin | 23.4% | 45.1% |
| Net Margin | 6.1% | 35.5% |
| Revenue YoY | 1.8% | 18.4% |
| Net Profit YoY | -16.3% | -55.9% |
| EPS (diluted) | $0.08 | $0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $110.6M | — | ||
| Q4 25 | $110.1M | $139.2M | ||
| Q3 25 | $109.6M | $134.2M | ||
| Q2 25 | $107.9M | $122.0M | ||
| Q1 25 | $108.6M | $114.8M | ||
| Q4 24 | $113.5M | $117.5M | ||
| Q3 24 | $122.8M | $119.8M | ||
| Q2 24 | $110.9M | $107.2M |
| Q1 26 | $6.7M | — | ||
| Q4 25 | — | $49.4M | ||
| Q3 25 | $4.5M | $36.4M | ||
| Q2 25 | $5.5M | $34.2M | ||
| Q1 25 | $42.5M | $26.9M | ||
| Q4 24 | — | $111.9M | ||
| Q3 24 | $16.7M | $35.9M | ||
| Q2 24 | $11.9M | $32.1M |
| Q1 26 | — | — | ||
| Q4 25 | 59.4% | 63.8% | ||
| Q3 25 | 60.5% | 56.3% | ||
| Q2 25 | 62.6% | 55.1% | ||
| Q1 25 | 62.0% | 53.2% | ||
| Q4 24 | 61.3% | 53.9% | ||
| Q3 24 | 65.5% | 49.8% | ||
| Q2 24 | 63.6% | 53.6% |
| Q1 26 | 23.4% | — | ||
| Q4 25 | 21.1% | 45.1% | ||
| Q3 25 | 22.6% | 38.0% | ||
| Q2 25 | 24.1% | 35.1% | ||
| Q1 25 | 66.3% | 30.4% | ||
| Q4 24 | 26.5% | 32.6% | ||
| Q3 24 | 30.8% | 33.1% | ||
| Q2 24 | 27.8% | 36.6% |
| Q1 26 | 6.1% | — | ||
| Q4 25 | — | 35.5% | ||
| Q3 25 | 4.1% | 27.1% | ||
| Q2 25 | 5.1% | 28.1% | ||
| Q1 25 | 39.2% | 23.4% | ||
| Q4 24 | — | 95.2% | ||
| Q3 24 | 13.6% | 30.0% | ||
| Q2 24 | 10.7% | 29.9% |
| Q1 26 | $0.08 | — | ||
| Q4 25 | $0.06 | $0.20 | ||
| Q3 25 | $0.07 | $0.15 | ||
| Q2 25 | $0.09 | $0.14 | ||
| Q1 25 | $0.70 | $0.11 | ||
| Q4 24 | $0.14 | $0.45 | ||
| Q3 24 | $0.28 | $0.15 | ||
| Q2 24 | $0.20 | $0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $118.3M | $87.6M |
| Total DebtLower is stronger | — | $72.1M |
| Stockholders' EquityBook value | $1.1B | $477.3M |
| Total Assets | $2.9B | $624.2M |
| Debt / EquityLower = less leverage | — | 0.15× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $118.3M | — | ||
| Q4 25 | $129.4M | $87.6M | ||
| Q3 25 | $138.7M | $61.4M | ||
| Q2 25 | $143.7M | $90.3M | ||
| Q1 25 | $143.9M | $71.6M | ||
| Q4 24 | $425.7M | $103.1M | ||
| Q3 24 | $533.0M | $86.7M | ||
| Q2 24 | $114.9M | $88.2M |
| Q1 26 | — | — | ||
| Q4 25 | $1.7B | $72.1M | ||
| Q3 25 | — | $72.4M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.0B | $72.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.2B | $477.3M | ||
| Q3 25 | $1.2B | $431.2M | ||
| Q2 25 | $1.2B | $398.3M | ||
| Q1 25 | $1.2B | $373.4M | ||
| Q4 24 | $1.2B | $349.0M | ||
| Q3 24 | $1.2B | $231.9M | ||
| Q2 24 | $1.2B | $188.3M |
| Q1 26 | $2.9B | — | ||
| Q4 25 | $2.9B | $624.2M | ||
| Q3 25 | $2.9B | $568.7M | ||
| Q2 25 | $3.0B | $558.4M | ||
| Q1 25 | $3.0B | $510.6M | ||
| Q4 24 | $3.3B | $488.7M | ||
| Q3 24 | $3.4B | $390.6M | ||
| Q2 24 | $3.0B | $376.4M |
| Q1 26 | — | — | ||
| Q4 25 | 1.48× | 0.15× | ||
| Q3 25 | — | 0.17× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.72× | 0.21× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $35.6M |
| Free Cash FlowOCF − Capex | — | $34.6M |
| FCF MarginFCF / Revenue | — | 24.8% |
| Capex IntensityCapex / Revenue | 14.5% | 0.8% |
| Cash ConversionOCF / Net Profit | — | 0.72× |
| TTM Free Cash FlowTrailing 4 quarters | — | $27.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $167.1M | $35.6M | ||
| Q3 25 | $40.5M | $13.3M | ||
| Q2 25 | $49.2M | $21.1M | ||
| Q1 25 | $36.9M | $-19.7M | ||
| Q4 24 | $207.1M | $50.2M | ||
| Q3 24 | $52.4M | $25.0M | ||
| Q2 24 | $59.3M | $45.6M |
| Q1 26 | — | — | ||
| Q4 25 | $94.9M | $34.6M | ||
| Q3 25 | $23.1M | $-1.1M | ||
| Q2 25 | $28.4M | $18.7M | ||
| Q1 25 | $20.4M | $-24.4M | ||
| Q4 24 | $136.9M | $47.5M | ||
| Q3 24 | $28.0M | $24.0M | ||
| Q2 24 | $43.6M | $43.6M |
| Q1 26 | — | — | ||
| Q4 25 | 86.2% | 24.8% | ||
| Q3 25 | 21.1% | -0.8% | ||
| Q2 25 | 26.3% | 15.3% | ||
| Q1 25 | 18.8% | -21.2% | ||
| Q4 24 | 120.7% | 40.4% | ||
| Q3 24 | 22.8% | 20.0% | ||
| Q2 24 | 39.3% | 40.7% |
| Q1 26 | 14.5% | — | ||
| Q4 25 | 65.6% | 0.8% | ||
| Q3 25 | 15.9% | 10.7% | ||
| Q2 25 | 19.3% | 2.0% | ||
| Q1 25 | 15.1% | 4.1% | ||
| Q4 24 | 61.9% | 2.3% | ||
| Q3 24 | 19.9% | 0.9% | ||
| Q2 24 | 14.1% | 1.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.72× | ||
| Q3 25 | 8.98× | 0.36× | ||
| Q2 25 | 9.01× | 0.62× | ||
| Q1 25 | 0.87× | -0.73× | ||
| Q4 24 | — | 0.45× | ||
| Q3 24 | 3.15× | 0.70× | ||
| Q2 24 | 4.98× | 1.42× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AAT
| Rental income | $104.4M | 94% |
| Other | $6.2M | 6% |
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
